lapatinib has been researched along with clomipramine in 4 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (clomipramine) | Trials (clomipramine) | Recent Studies (post-2010) (clomipramine) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 2,929 | 541 | 304 |
| Protein | Taxonomy | lapatinib (IC50) | clomipramine (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.034 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 0.071 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.241 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 0.091 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.053 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.707 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 3.9465 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 0.091 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.413 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.005 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0505 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.7065 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.005 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 0.17 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 1.113 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0678 | |
| Histamine H2 receptor | Homo sapiens (human) | 2.049 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.18 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.067 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.034 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0002 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.035 | |
| 5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.005 | |
| 5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.005 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.085 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.139 | |
| 5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.005 | |
| Trypanothione reductase | Trypanosoma brucei brucei | 3.4 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.239 | |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 0.72 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 0.245 | |
| Voltage-dependent N-type calcium channel subunit alpha-1B | Homo sapiens (human) | 9 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.7615 | |
| 5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.005 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.362 | |
| 5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for lapatinib and clomipramine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for lapatinib and clomipramine
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |